Ziyaeyan Mazyar, Alborzi Abdolvahab, Japoni Aziz, Kadivar Mohammad, Davarpanah Mohammad Ali, Pourabbas Bahman, Abassian Amin
Professor Alborzi Clinical Microbiology Research Center and Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Int J Dermatol. 2007 Dec;46(12):1263-6. doi: 10.1111/j.1365-4632.2007.03449.x.
Herpes simplex virus (HSV) infections are usually chronically recurrent in the normal population and represent a significant cause of morbidity in immunocompromised patients. Acyclovir (ACV) is widely used for the treatment and prophylaxis of HSV infections. The emergence of ACV-resistant strains has been frequently reported as a result of long-term ACV therapy.
Despite the widespread use of ACV, there are no data available in our area on the frequency of ACV-resistant HSVs. The purpose of this study was to evaluate the susceptibility of HSV isolated from normal subjects and patients with acquired immunodeficiency syndrome (AIDS) to ACV.
HSVs were isolated from the orofacial region of normal individuals and patients with AIDS. The susceptibility of isolated HSV strains to various concentrations of ACV was determined by plaque reduction assay. The sensitivity of the viral strains was expressed as IC(50) (the concentration of drug reducing the viral plaque by 50%).
One hundred and thirty-three isolates from 102 normal subjects and 31 patients with AIDS were tested. One HSV-1 isolate from normal individuals had intermediate susceptibility. Two ACV-resistant isolates (one HSV-1 and one HSV-2), with IC(50) > or = 2 to < or = 3 microg/mL, and one highly resistant HSV-2 isolate, with IC(50) > or = 5 microg/mL, were detected in patients with AIDS.
Our data show that the prevalence of ACV-resistant strains is very low in the general immunocompetent population; however, in patients with AIDS, the prevalence of ACV-resistant strains is remarkable (P = 0.001). Alternative antiherpetic agents should be employed to control and reduce the emergence of ACV-resistant strains in patients with AIDS.
单纯疱疹病毒(HSV)感染在正常人群中通常呈慢性复发,并且是免疫功能低下患者发病的重要原因。阿昔洛韦(ACV)被广泛用于治疗和预防HSV感染。长期使用ACV治疗导致ACV耐药菌株的出现屡有报道。
尽管ACV已广泛应用,但我们地区尚无关于ACV耐药HSV频率的数据。本研究的目的是评估从正常受试者和获得性免疫缺陷综合征(AIDS)患者中分离出的HSV对ACV的敏感性。
从正常个体和AIDS患者的口面部区域分离HSV。通过蚀斑减少试验测定分离出的HSV菌株对不同浓度ACV的敏感性。病毒株的敏感性以IC50(使病毒蚀斑减少50%的药物浓度)表示。
对来自102名正常受试者和31名AIDS患者的133株分离株进行了检测。从正常个体中分离出的1株HSV-1具有中等敏感性。在AIDS患者中检测到2株ACV耐药分离株(1株HSV-1和1株HSV-2),IC50≥2至≤3μg/mL,以及1株高度耐药的HSV-2分离株,IC50≥5μg/mL。
我们的数据表明,在一般免疫功能正常人群中,ACV耐药菌株的流行率非常低;然而,在AIDS患者中,ACV耐药菌株的流行率显著(P = 0.001)。应采用替代抗疱疹药物来控制和减少AIDS患者中ACV耐药菌株的出现。